

NOV 30 2005



GlaxoSmithKline

FAX

To Examiner: Brenda Libby COLEMAN Group: 1624

Company USPTO

Fax 571-273-8300

From Andrea N. Scoggins

Tel 1-919-483-9552; Facsimile: 1-919-483-7977

E-mail andrea.n.scoggins@gsk.com

Date November 30, 2005 Pages including cover 5

Subject Corrected Filing Receipt

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com

Re: Application of: Rachel ANNCLIFF et. al
U.S. Serial No.: 10/531,758 Filed: April 4, 2005
Title: Substituted Piperazines (1, 4) Diazepines, and
2, 5 - Diazabicyclo (2.2.1) Heptanes as Histamine
H1 and /or H3 Antagonists or Histamine H3 reverse
Antagonists.

Attorney Docket No.: P33126USw

Attached:

1. Request Corrected Filing Receipt (1 page)
2. Copy of Filing Receipt (3 pages)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Atty. Dkt. No. P33126USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rachel ANNCLIFF et al.

Serial No.: 10/531,758

Unit: 1615

Filed:

Examiner:

For: Substituted Piperazines (1, 4) Diazepines, and
2, 5 - Diazabicyclo (2.2.1) Heptanes as Histamine
H1 and/or H3 Antagonists or Histamine H3 reverse
Antagonists.

RECEIVED
CENTRAL FAX CENTER
NOV 30 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

2. There is an error with respect to the following data, which is:

☒ Incorrectly entered

and/or

☐ omitted.

Error in

1. ☒ Applicant's name

2. ☐ Applicant's address

3. ☒ Title

4. ☐ Filing date

5. ☐ Serial Number

6. ☐ Foreign/PCT Application Re:

7. ☐ Other:

Correct data

1. Colin David Eldred, Stevenage, United Kingdom
Yvonne C. Fogden, Stevenage, United Kingdom
Ashley Paul Hancock, Stevenage, United Kingdom
Thomas Daniel Heightman, Harlow, United Kingdom
Simon Teanby Hodgson, Stevenage, United Kingdom
Matthew J. Lindon, Stevenage, United Kingdom
David Matthew Wilson, Harlow, United Kingdom

2.


3. Substituted Piperazines (1, 4) Diazepines, and
2, 5 - Diazabicyclo (2.2.1) Heptanes as
Histamine H1 and/or H3 Antagonists or Histamine
H3 Reverse Antagonists.

4.

5.

6.

7.



James P. Riek

Registration No.: 39,009

Date: November 30, 2005

GlaxoSmithKline

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709

Phone: 919-483-2474

Fax: 919-483-7988

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted or deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: M/S XXX, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: November 30, 2005



ANDREA N. SCOGGINS

Early Publication Request: No

Title

Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) ^{heptanes} heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).